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EDITORIAL COMMENT
Coronary Vasospasm
Not Gone But Often Forgotten*
Michael P. Savage, MD,a Tabitha G. Moe, MDb
I t has been more than 60 years since the initialdescription of vasospastic angina by Prinzmetalet al. (1). This seminal report was a series of 32
patients with a clinical syndrome characterized by
angina occurring at rest associated with transient
ST-segment elevation and prompt relief with nitro-
glycerin. Classified as a “variant form of angina” to
distinguish it from the classic exertional angina of
Heberden, the researchers astutely postulated that
the cause of these attacks was a “temporary increased
tonus” in large coronary arteries.
Although the prevalence of coronary artery spasm
(CAS) is unknown, evidence suggests that it remains
underdiagnosed and undertreated. A large registry
study showed that 62% of patients undergoing elec-
tive cardiac catheterization for suspected coronary
artery disease had no obstructive disease (2). A pro-
spective study of 124 patients with typical angina but
angiographically normal coronary arteries evaluated
the frequency of provocable CAS using intracoronary
acetylcholine (3). Epicardial CAS was demonstrated in
28% of patients. An additional 34% of patients had
evidence of microvascular spasm. Similarly, in the
CorMICA (Coronary Microvascular Angina) trial,
acetylcholine testing induced epicardial vasospasm in
37% of patients with angina but no obstructive coro-
nary artery disease (4). Despite the accruing evidence
for CAS as a frequent cause of chest pain in patients
with relatively normal coronary angiograms, provoc-
ative testing with acetylcholine or ergot derivatives is
infrequently performed in contemporary practice. In
addition to recurrent symptomatic episodes, CAS may
cause myocardial infarction or sudden cardiac death,
and therefore, failure of diagnosis can have poten-
tially dire consequences.
Another variation on the theme of unrecognized
CAS is seen in patients with chest pain syndromes
and significant angiographic stenosis. Vishnevsky
et al. (5) described a series of patients referred for
percutaneous coronary intervention (PCI) with >70%
stenosis on angiography that resolved after adminis-
tration of intracoronary nitroglycerin. PCI was de-
ferred, and patients were successfully treated with
medication. The importance of considering CAS dur-
ing diagnostic cardiac catheterization was further
illustrated by Mohammed et al. (6), who found that in
patients with prior coronary artery bypass grafting
(CABG) for left main stenosis, 4.1% had no evidence of
left main disease on follow-up coronary angiography,
suggesting that vasospasm was responsible for the
original lesion (6). Other investigators have reported
even higher rates of unrecognized left main vaso-
spasm in patients referred for CABG (7). These studies
underscore the importance of intracoronary nitro-
glycerin during diagnostic coronary angiography and
before PCI to avert unnecessary revascularization
procedures (8). It is notable that current PCI guide-
lines neglect to mention the use of intracoronary
nitroglycerin, which has been dubbed the “forgotten
stepchild of cardiovascular guidelines” (5).
This issue of JACC: Case Reports presents 2 case
studies of patients with coronary vasospasm offering
different, important perspectives. The report by Arps
et al. (9) reinforces past lessons on the importance of
clinical vigilance for the role of vasospasm in chest
pain syndromes, and the report by Pereyra et al. (10)
points the way toward future novel approaches for
the treatment of CAS.
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Arps et a. (9) describe a 69-year-old man under-
going cardiac catheterization for unstable angina 7
years after CABG. Initial injection of the vein graft to a
diagonal branch demonstrated a high-grade proximal
stenosis and was complicated by ventricular fibrilla-
tion. After resuscitation, PCI was initiated, but repeat
angiography following coronary guidewire placement
revealed complete return of vein graft patency, indi-
cating that the original stenosis was due to vaso-
spasm. A common perception is that spasm of
aortocoronary venous bypass grafts is relatively rare
outside of the early post-operative period. However,
cases of vein graft spasm have long been recognized
(11,12). Kafka et al. (13) reported vein graft spasm in 24
of 1,264 (1.9%) patients undergoing routine post-
CABG surveillance angiography. The location of
spasm was typically in the proximal grafts, which
were often technically difficult to engage, suggesting
that catheter-induced spasm was the proximate cause
in many of the cases.
This case report has valuable take-home lessons.
The possibility of CAS needs to be considered even in
cases where itmay be least expected. Vein graft spasm,
although uncommon, does occur, and failure to make
the diagnosis could lead to unnecessary stenting (8).
The present report is a case in point—vasospasm was
not initially considered, as PCI had commenced, until
repeat angiography showed spontaneous resolution of
the stenosis. A more advisable action during this pro-
cedure would have been to administer intracoronary
nitroglycerin first before proceedingwith PCI precisely
for this reason (5). Fortunately, CAS was recognized,
and the patient was treated successfully with medi-
cation. PCI and stents are generally not recommended
for the treatment of CAS in the absence of severe
atherosclerotic disease. In patients with CAS, PCI does
not eliminate the need for continued antispasm
medication because spasm has the propensity to
reoccur outside of the stented segment (14).
Management of vasospastic angina includes
avoidance of precipitating factors, especially ciga-
rette smoking and drugs that potentiate coronary
vasoconstriction, such as cocaine, sympathomimetic
agents, ergot alkaloids, and nonselective beta-
blockers (15). Magnesium deficiency has also been
associated with vasospastic angina. Calcium-channel
blockers and nitrates are the mainstays of therapy
for CAS. Occasionally, patients fail to achieve an
adequate response despite combination therapy with
these drugs. In Japan, where CAS is more prevalent,
the incidence of intractable vasospastic angina ex-
ceeds 13% (16). One strategy for dealing with re-
fractory vasospastic angina is to use different
calcium-channel antagonists (dihydropyridine and
nondihydropyridine) in combination. There is a
paucity of data on the efficacy of this approach, and
new alternative options are needed to address the
difficult problem of vasospastic angina refractory to
conventional therapies.
The case report by Pereyra et al. (10) describes the
novel use of riociguat to successfully treat a 77-year-
old woman with refractory vasospastic angina. Rio-
ciguat is an oral drug, a soluble guanylate cyclase
stimulator approved for the treatment of pulmonary
arterial hypertension (PAH) in World Health Organi-
zation (WHO) group 1 patients. It is the only agent
approved by the U.S. Food and Drug Administration
for WHO group 4 patients with chronic thromboem-
bolic pulmonary hypertension. The drug has been
shown to improve exercise capacity and WHO func-
tional class and to delay clinical worsening in patients
with PAH (17,18).
In this case study, riociguat was used off label to
treat longstanding vasospastic angina that was re-
fractory to multiple conventional drugs. Riociguat
promotes vasodilation via cyclic guanosine mono-
phosphate, which is produced in lung parenchyma by
guanylate cyclase in response to nitric oxide. Rioci-
guat increases the activity of soluble guanylate
cyclase by 2 mechanisms: it sensitizes soluble gua-
nylate cyclase to endogenous nitric oxide and also
directly stimulates guanylate cyclase receptors inde-
pendent of nitric oxide (18). That the vasodilatory
effects occur systemically and not only in the pul-
monary circulation allows its potential as a thera-
peutic agent in the treatment of coronary vasospasm.
Other agents affecting this nitric oxide pathway may
also be potential therapeutic targets. In the United
States, riociguat remains on patent and is not a
preferred agent by many insurance providers,
resulting in what is often a cost-prohibitive therapy
for patients with PAH.
Larger controlled studies are necessary before rio-
ciguat can be recommended for the treatment of CAS.
The drug has notable side effects and drug in-
teractions. Secondary to the systemic effects of vaso-
dilation, hypotension, headaches, and vasomotor
symptoms are not uncommon. The application may be
limited in patients with elevated left ventricular end-
diastolic pressure (LVEDP) because it is likely to
worsen LVEDP. Riociguat potentiates the blood
pressure–lowering effect of nitroglycerin, which is
particularly problematic for patients with CAS because
its use is contraindicated “with nitrates or nitric oxide
donors in any form” (19). Riociguat utilizes the CYP3A
pathway. Therefore, ketoconazole and protease in-
hibitors increase circulating levels of riociguat.
Conversely, nicotine exposure decreases circulating
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levels of riociguat. For smokers, dosage adjustments
may be necessary unless smoking cessation can be
achieved. Bioavailability may be affected by antacids
containing magnesium or aluminum hydroxide,
which limit absorption. Particular caution is required
in women of child-bearing age. The drug is pregnancy
category X and requires additional monitoring for all
women of reproductive potential.
In conclusion, coronary artery spasm remains alive
and well. The case studies presented in this issue of
JAAC: Case Reports serve to underscore the continued
challenges in the diagnosis and treatment of this
affliction. Continued cognizance of the often sneaky
role of vasospasm in chest pain syndromes is vital to
ensure its clinical recognition and appropriate
therapy.
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